Signs of clinical efficacy after treatment with IL-15 and alemtuzumab. (A) Swimmers’ plot of all trial participants during on-study follow-up. (B) FDG-PET and clinical photograph of a patient with chronic subtype ATL before and 3 months after treatment. (C) Leukemic cell count during and after treatment with IL-15 and alemtuzumab represented as fold-change from baseline in absolute number of ATL cells detected by flow cytometry. Images published with study participant’s consent.